Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.

ABSTRACT:

Importance

Antidepressant use may be associated with reduced levels of several proinflammatory cytokines suggested to be involved with the development of severe COVID-19. An association between the use of selective serotonin reuptake inhibitors (SSRIs)-specifically fluoxetine hydrochloride and fluvoxamine maleate-with decreased mortality among patients with COVID-19 has been reported in recent studies; however, these studies had limited power due to their small size.

Objective

To investigate the association of SSRIs with outcomes in patients with COVID-19 by analyzing electronic health records (EHRs).

Design, setting, and participants

This retrospective cohort study used propensity score matching by demographic characteristics, comorbidities, and medication indication

SUBMITTER: Oskotsky T 

PROVIDER: S-EPMC8593759 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature